VUMERITY Drug Patent Profile

Which patents cover Vumerity, and when can generic versions of Vumerity launch?

Vumerity is a drug marketed by Biogen and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in thirty-one countries.

The generic ingredient in VUMERITY is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vumerity

A generic version of VUMERITY was approved as diroximel fumarate by ZYDUS on November 12^th, 2025.

Summary for VUMERITY

International Patents:	61
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VUMERITY

Paragraph IV (Patent) Challenges for VUMERITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VUMERITY	Delayed-release Capsules	diroximel fumarate	231 mg	211855	1	2020-12-23

US Patents and Regulatory Information for VUMERITY

VUMERITY is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes			Y	Y
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes			Y	Y

International Patents for VUMERITY

When does loss-of-exclusivity occur for VUMERITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VUMERITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014239641
Australia	2016222363
Australia	2018200497
Brazil	112015022854
Canada	2906580

Supplementary Protection Certificates for VUMERITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2970101	CA 2022 00010	Denmark		PRODUCT NAME: DIROXIMELFUMARAT; NAT. REG. NO/DATE: EU/1/21/1585 20211116; FIRST REG. NO/DATE: CH 68066 20210920
2970101	PA2022003	Lithuania		PRODUCT NAME: DIROKSIMELIO FUMARATAS ; REGISTRATION NO/DATE: EU/1/21/1585 20211115
2970101	2290010-4	Sweden		PRODUCT NAME: DIROXIMELFUMARAT; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/21/1585, 2021-11-16; PRV HAR FATTAT BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2290042-7 2290031-0 1590027-7 1590062-4 2190040-2 2290010-4 1990014-1 2190030-3 1590011-1 1490013-8 1490014-6 1490015-3 1890033-2 1990042-2 1990055-4 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
2970101	2022C/507	Belgium		PRODUCT NAME: DIROXIMEL FUMARATE; AUTHORISATION NUMBER AND DATE: EU/1/21/1585 20211116
2970101	8/2022	Austria		PRODUCT NAME: DIROXIMELFUMARAT; NAT. REGISTRATION NO/DATE: EU/1/21/1585 (MITTEILUNG) 20211116; FIRST REGISTRATION: LI 68066 (CH) 20210920

VUMERITY (diroximel fumarate) Investment Scenario and Fundamentals Analysis: Sales Drivers, Patent Cliff, Generic/Biosimilar Risk, and Licensing/Competition Outlook

Last updated: July 16, 2026

Executive summary: VUMERITY (diroximel fumarate) generates revenue tied to Tecfidera-class fumarate tolerability, payer adoption, and patient persistence after switching from dimethyl fumarate (DMF). The investment case is anchored by (1) ongoing high share in US oral MS and neurology formularies, (2) moderate exclusivity over remaining years with specific Orange Book protection layers on formulations and methods, and (3) limited near-term generic pressure given FDA labeling fragmentation and patent/Paragraph IV dynamics typical for fumarates. The downside is patent expiry over time plus erosive competition from Tecfidera, generics of DMF where available, and other oral MS entrants that pressure dosing convenience, safety profile, and contracting leverage.

---

What is VUMERITY’s role in multiple sclerosis and why does it move revenue?

VUMERITY is an oral fumarate indicated for relapsing forms of multiple sclerosis (RMS). It is positioned against dimethyl fumarate (Tecfidera) and other oral RMS therapies. Revenue fundamentals in US neurology are driven by three variables: (1) payer placement and net price, (2) patient switch and persistence, and (3) utilization constraints from safety and adverse-event management.

RMS payer economics and channel reality

• Oral MS revenues depend on contracting cadence with PBMs and large integrated payers, which determine formulary tiers, prior authorization (PA) burden, and step edits.
• Fumarates typically compete on gastrointestinal (GI) tolerability and flushing risk, which affects adherence and persistence and, in turn, net sales.

Product differentiation that matters for uptake

• VUMERITY’s value proposition is “better tolerability versus older DMF” in real-world patient experience, which can support formulary placement and patient switching.
• For investors, the measurable proxy is persistence and refill behavior after initial stabilization, not just launch uptake.

---

How strong are VUMERITY sales fundamentals: growth, mix, and persistence?

A defensible fundamentals view for VUMERITY requires tying revenue to patient counts, adherence, and net pricing. For the investment case, the key is whether VUMERITY is increasing share among oral RMS initiations and switches, and whether formulary loss risk is rising.

Core drivers that support topline

1. Switching from DMF when patients experience GI adverse events or flushing.
2. New starts where payer coverage is favorable and “fumarate” is preferred within oral RMS segments.
3. Lower discontinuation relative to earlier fumarate experiences, supporting retention economics.

Core risks that reduce revenue

1. Formulary displacement by other oral classes (S1P modulators) that can offer higher efficacy and/or different safety tradeoffs under payer criteria.
2. Increased cost scrutiny: PBMs push annual caps, step therapy, and higher coinsurance for premium-priced oral neurology drugs.
3. Safety-related interruptions that reduce adherence.

What investors should track operationally

• Script volume trend and refill adherence rate.
• PA approval rates and denials (proxy for contracting friction).
• Net price trajectory versus list price due to rebates and patient assistance changes.

---

What patents protect VUMERITY and what is the scope of Orange Book exclusivity?

VUMERITY is protected by a layered IP stack typical of branded oral drugs: active ingredient-related claims, formulation/process claims, and sometimes use-related claims. The Orange Book protection determines the legal barriers to generic entry.

What patents typically appear in the Orange Book for this drug class

For fumarates, patent estates usually cover:

• Solid-state and formulation characteristics
• Dosage forms and release properties
• Manufacturing and process parameters
• Method-of-use claims that align with FDA labeling for RMS

How to read the “protective stack” for investment risk

• If early-expiring patents expire while core formulation claims remain, generic entry can be delayed or limited to non-infringing variants.
• If Orange Book lists multiple expiring soon, the risk is a faster generic entry wave and revenue cliff.

---

When does VUMERITY lose exclusivity and what is the patent expiration timeline?

The exclusivity calendar is the principal investment timing variable. Investors should align internal models to:

• First non-exclusivity date for each Orange Book patent (where “skinny” or redesigned generics could enter)
• Expected “first generic” date tied to ANDA filing timing and litigation outcomes
• Potential label changes that can trigger additional exclusivity or re-filing risk

Patent cliff mechanics that matter

• Loss of exclusivity on a key formulation or method-of-use patent increases likelihood of an ANDA carve-out and launch.
• Even after patent expiry, exclusivity linked to regulatory exclusivity (where applicable) can extend market protection depending on FDA determinations.

---

What patent litigation affects VUMERITY, including Paragraph IV challenges?

For investments, generic entry risk is best modeled through the Paragraph IV pathway:

• ANDA filers challenging Orange Book-listed patents
• Court outcomes: dismissal, settlement, consent judgment
• Trigger events for “design-around” products

Litigation scenarios and their revenue impact

• Filer loses or case dismissed: entry delayed; brand retention supported.
• Settlement with delayed entry: predictable “pay-to-delay” style timing that anchors revenue forecasts.
• Partial win or design-around: can trigger launch with limited competitive overlap.

Investor modeling of litigation probability

• Litigation risk rises when multiple Orange Book patents approach expiry.
• Risk also increases if courts have already construed key claims in related DMF/fumarate cases.

---

What generic entry risks exist for VUMERITY and how likely is a price drop?

The generic threat is not binary. It has three practical dimensions: ANDA approval path, label/claim design, and contracting impact on net pricing.

Key scenarios for generic pressure

1. Generic launch after patent expiry with intact labeling: likely fastest route to significant price competition.
2. Generic launch with altered formulation/dosing constraints: may slow uptake if real-world interchangeability is constrained by payer policies.
3. Delayed entry via litigation settlement: revenue curve bends down later, not immediately.

Why price erosion can lag regulatory approval

• Even with FDA approval, PBM adoption can be slower if clinical preference or switching inertia exists.
• Manufacturers may maintain rebates and support patient services that reduce near-term net price shock.

---

How does VUMERITY compare with Tecfidera and other fumarates on commercial risk?

VUMERITY competes directly with DMF products. The comparative investment question is whether VUMERITY is gaining share or losing it within the fumarate segment as DMF generics proliferate and other MS classes expand.

Tecfidera vs VUMERITY: investment implications

• If Tecfidera’s market is more exposed to generic substitution, VUMERITY can benefit via switching for tolerability.
• If VUMERITY is less exposed legally than Tecfidera during the same period, the combined category can behave differently from a generic replacement standpoint.

Competitive pressure from non-fumarate oral MS drugs

• Oral MS competition shifts with payer preferences for safety, adherence, and monitoring burden.
• The investment case is strongest when VUMERITY keeps formulary position despite competitor efficacy narratives.

---

What formulations and dosage forms are protected for VUMERITY?

Formulation patents are the most actionable IP drivers for design-around risk. For oral drugs, protected attributes frequently include:

• Tablet composition, excipients, and ratios
• Release or stability characteristics
• Manufacturing method that ensures bioavailability

What this means for generics

• A generic must either match a protected formulation (higher infringement risk) or show no infringement through design-around (slower development, higher litigation probability).
• If formulation claims are broad, generic entry timing is more predictable and brand life is longer.

---

What method-of-use or label-related patents cover VUMERITY?

Method-of-use claims can constrain “skinny label” entry if they track the FDA indication precisely. The economic effect is direct: if label scope is locked by patent claims, generics can’t launch without a narrower label or litigation.

Investment impact of method-of-use claim breadth

• Broad use claims make it harder to launch even after formulation expiries.
• Narrow use claims can allow generic entry with partial labeling, reducing competitive intensity.

---

What is the Orange Book status of VUMERITY and how many patents block generic entry?

Orange Book status should be treated as a count and maturity problem:

• Count of patents per NDA
• Expiry dates clustering
• Patent claim coverage categories: active ingredient, formulation, method-of-use, manufacturing

How to use the Orange Book “cluster” concept

• A dense clustering of patents around similar dates is a cliff risk event.
• A spread across years creates a step-down revenue pattern instead of a single drop.

---

What manufacturing and IP barriers could slow generic implementation for VUMERITY?

Beyond patents, practical barriers can affect generic competitiveness:

• Process complexity for a protected solid form or conversion step
• Stability and bioequivalence challenges for fumarate derivatives
• Need to manage GI tolerability and dissolution profiles during scale-up

Why these barriers matter for net sales

• Even with patent expiry, slower generic ramp can reduce the magnitude and speed of price erosion.
• Limited early generic supply can preserve payer and patient access to brand product.

---

How does VUMERITY’s safety and tolerability profile affect long-term demand?

Safety is commercial. For oral fumarates:

• GI events and flushing influence adherence.
• Discontinuation rates influence the active-patient pool.

What investors should watch in real-world evidence

• Treatment persistence at 6-12 months after switch or initiation
• Dose interruption patterns and supportive medication usage
• Hepatic or lymphocyte-related monitoring burden affecting provider workflows

---

What licensing, exclusivity, and deal terms shape VUMERITY’s business outlook?

VUMERITY’s commercial strategy can be influenced by how the branded product is licensed, distributed, or co-marketed in different geographies. For an investment model, deal exposure matters where:

• A partner controls manufacturing or supply
• Royalties flow upstream and affect margin stability
• Transition arrangements occur around exclusivity changes

---

What FDA regulatory pathway milestones could change the competitive landscape?

Regulatory milestones influence generics and brand-label outcomes:

• FDA approvals of supplemental indications or label changes can create additional IP protection opportunities through new patents tied to the label
• Changes in interchangeability guidance or labeling format can shift substitution patterns

Practical regulatory effects on revenue

• Label expansions can add patient pool, but they can also invite faster generic litigation
• Safety label changes can impact market access through PA or step therapy modifications

---

How strong is the patent estate for VUMERITY vs its closest competitive threats?

An investment-quality comparison ranks patent estates along two axes:

1. Time to key expiry events
2. Breadth of claim categories (ingredient vs formulation vs method-of-use)

Competitive estate mapping (framework investors can use)

• VUMERITY estate strength is strongest when:
  • Formulation/method-of-use patents extend beyond closest competitor’s barriers
  • Expiry dates do not cluster tightly into a single cliff year
• Estate risk increases when:
  • Multiple Orange Book patents expire in a short window
  • Litigation results in claim narrowing or invalidation

---

Key data model for investors: revenue exposure to the patent clock

Investment scenario matrix (generic entry risk vs revenue impact):

Scenario	Entry timing trigger	Legal posture	Competitive intensity	Revenue impact pattern
Base case	Entry delayed by litigation/settlement	Branded maintains exclusivity in formulation/use	Moderate	Gradual step-down
Accelerated	Clustered expiries + favorable ANDA outcomes	Multiple patents fall in a short window	High	Sharp decline after expiry
Defensive	Sustained protective stack + design-around blocks	Litigation settlements delay launch	Moderate to low	Flatter decline
Erosion from non-IP	PBM formulary shifts to other oral MS classes	No direct patent defeat needed	Medium	Mix shift and net price compression

---

Key Takeaways

• VUMERITY’s revenue durability depends on patient persistence from fumarate tolerability economics and on whether payer access remains stable versus other oral RMS options.
• The patent clock, as expressed through Orange Book listings, is the primary determinant of generic entry timing and the magnitude of price erosion.
• The strongest downside risk is an Orange Book cluster with adverse Paragraph IV outcomes that accelerates generic ramp.
• The strongest upside comes from switching dynamics from DMF and sustained formulary placement that offsets competitor efficacy pressure until exclusivity expiries.

---

FAQs

1) How much of VUMERITY demand depends on switching from dimethyl fumarate tolerability failures?
Switching is a core contributor in fumarate segments, and it can support retention if payer coverage remains favorable post-switch.

2) What is the most likely generic launch pattern for VUMERITY after key patent expiries?
A staged ramp is more common than immediate full substitution due to PBM adoption cycles, litigation posture, and supply readiness.

3) Which patent category is most likely to block generic entry for VUMERITY: formulation, method-of-use, or manufacturing?
Formulation and method-of-use categories typically carry the highest design-around burden for oral MS drugs.

4) How do MS competitor launches change VUMERITY’s net pricing and formulary position?
They can trigger tighter PBM contracting, increased PA scrutiny, and step therapy that compress net price even without direct generic substitution.

5) What regulatory events are most relevant to VUMERITY’s competitive risk timeline?
Label expansions or safety label modifications tied to supplemental approvals can shift PA criteria and alter how quickly generics are commercially adopted.

---

References

(No sources were provided in the prompt.)